Grunenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grunenthal invested USD 14.5 million to build the 1,150 m 2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America.